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Abstract 
Primary tumour calcinosis is a rare condition of unknown etiopathogeny. They are transmitted in an autosomal 
dominant or recessive mode and predominate in the black race. Calcinoses are manifested by hydroxyapathite 
deposits in the dermis or hypodermis. The authors report an observation of primary tumour calcinosis associated 
with renal abnormalities and staturoweight retardation in an 11-year-old child.  
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1. Introduction  
Tumourous calcinosis is a rare condition that affects black adolescents or adults [1]. There are several types of 
tumor calcinosis and their nosology is not well defined. Tumor calcinosis can be primary or secondary, isolated 
or associated with other conditions [23]. The characteristic feature of tumour calcinosis is the dermal or 
hypodermal deposition of hydroxyapathite. Primary tumour calcinosis is described as TEUSCHLANDER's 
lipocalcinogranulomatosis with associated metabolic disorders [5]. The authors report a case of tumour 
calcinosis associated with renal abnormalities in an 11-year-old child. 
2. Observation  
An 11-year-old black boy was admitted to a dermatology consultation at Brazzaville University Hospital for 
diffuse hypopigmented macules associated with a diffuse, predominantly acral skin sclerosis that had been 
evolving for 6 years. 
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The general condition was preserved, he was not mentally retarded, his height was 1.28m, weighed 26 Kilos, a 
standard deviation of -3. The interrogation had been regaining the notion for 2 - 3 months of thirst, of abundant 
urination. Blood pressure was 80/60 mmHg.  The examination found voluminous masses evolving over the last 
5 years from 2 to 10 cm in diameter at the hips, knees, elbows and at the upper 1/3 of the right leg, of firm 
consistency, some ulcerated pseudoguminous masses with an inhomogeneous whitish and chalky background. 
The paraclinical assessment showed: blood glucose 1g/l, positive glycosuria, creatinine 6mg/l, low serum 
calcium 78 mg/l, low phosphorus 20 mg/l, kalaemia 3 mmol/l, natraemia 134 mmol/l, low proteinuria 0.23 
g/24h (9 mg/kg/d). Calciuria was elevated above 0.1 mmol/Kg/24h as was phosphaturia, diuresis at 2.3 l/24h. 
Standard radiography of the pelvis showed multiple calcifications (photo). The diagnosis of lipocalcino 
granulomatosis was suggested to be associated with proximal tubalopathy and staturoweight retardation. 
3. Discussion  
Tumor calcinosis or lipocalcino granulomatosis is a rare, benign condition characterized by the deposition of 
calcium material in extra-articular soft tissues in tumor form [5]. It may be primary or secondary to chronic 
renal failure. Heredity is found in 30% of cases. Transmission is autosomal recessive or dominant according to 
the authors with variable penetrance [7]. Three types of mutations have been identified, one affecting fibroblast 
growth factor 23 (FGF23) [8], the second affecting the phosphaturic hormone and glycosyl transferase GALT3 
and the phosphatemic form linked to the SAM D9 gene [8,9]. Disturbances in phosphate metabolism may 
accompany some tumor calcinosis [10]. Hyperphosphatemia is the rule [11,12], often secondary to chronic renal 
failure and hyperparathyroidism. The hypophosphatemia and hyperphosphatemia found in our observation are 
unusual. The existence of normo-glycemic glycosuria, hypercalciuria and hypocalcemia are evidence of an 
associated proximal aublopatia. Is this an incidental association of tumour calcinosis and proximal tubulopathy 
or an unusual type of mutation? Staturoponderal retardation has never been described in classical forms of 
tumour calcinosis. It is a manifestation of the hydroeletrolytic disorders associated with proximal tubulopathy. 
Our observation is unusual because of the coexistence of staturoweight retardation and tumour calcinosis. The 
occurrence of proximal tubulopathy is paradoxical in the course of tumour calcinosis; it may be related to an 
exceptional form or may be the translation of an unknown underlying hereditary pathology. We haven't found 
any link to a sickle cell trait. Hemoglobin electrophoresis was normal. Our limited means of investigation did 
not allow us to investigate genetics. 
4. Conclusion  
This observation illustrates the rarity of the association of tumour calcinosis and proximal tubulopathy with 
staturoweight retardation. Exhaustive genetic and metabolic investigations are essential for a better 
etiopathogenic and therapeutic approach. The relevant or fortuitous link of this association remains to be 
determined. 
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